Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Proshares Trust (ZBIO) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for Zenas BioPharma (ZBIO) over the last 3 years, with Q1 2025 value amounting to 336.26%.

  • Zenas BioPharma's EBITDA Margin changed N/A to 336.26% in Q1 2025 from the same period last year, while for Sep 2025 it was 1266.81%, marking a year-over-year change of. This contributed to the annual value of 3136.62% for FY2024, which is 30625300.0% down from last year.
  • Zenas BioPharma's EBITDA Margin amounted to 336.26% in Q1 2025.
  • Zenas BioPharma's EBITDA Margin's 5-year high stood at 71.23% during Q3 2023, with a 5-year trough of 1049.26% in Q4 2024.
  • Over the past 3 years, Zenas BioPharma's median EBITDA Margin value was 336.26% (recorded in 2025), while the average stood at 438.1%.